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THE NATIONAL HUMAN GENOME
Research Institute (NHGRI) wisely develops long-term plans with input from researchers from many walks of science. It has been a genome community tradition since before there was a Human Genome Project, and NHGRI should indeed be commended for it.
The format of the NHGRI draft presented to the November 2002 meeting was very confusing, however. Conference organizers made clarifying it a top priority. After working almost all night, they came up with a new formatthe metaphor of floors in a building that Ullmann and her colleagues describe-that was "inspirational" in that it better communicates what NHGRI and its constituents propose to do.
What were not fixed, and not really fully addressed by the group, were the issues covered in my article, such as how far into clinical research NHGRI should venture, or if the institute can really take on all that it proposes to do in the next 5 years. Those questions were raised by many participants both in public and private. Their resolution, not how the plan will look on paper, is what will determine NHGRI's effectiveness in the post-human genome era.
ELIZABETH PENNISI
Consensus and Ancestral
State HIV Vaccines THE REVIEW BY B. GASCHEN ET AL. ("DIVERSITY considerations in HIV-1 vaccine selection," 28 June, p. 2354) describes two computational methods (consensus and ancestral state) being considered for developing vaccine antigens against HIV. These methods attempt to minimize the amount of sequence divergence (distance) between the antigen and contemporaneously circulating viruses. Both methods do well at minimizing these distances when the sequences used to estimate the potential vaccine come from a symmetric phylogeny (panels A and B of the figure), similar to those examined in their Review. However, if sequences used to estimate the potential vaccine come from asymmetric phylogenies (panels C and D), then both methods generate sequences that poorly minimize these distances, making for a potentially poor vaccine antigen.
We have proposed and championed the ancestral state method (1-3), believing that it has an advantage over a consensus vaccine because the ancestral state is an estimate of an actual sequence that existed in the past (i.e., it comes directly from the reconstructed history), whereas the consensus sequence need not be, and most likely is not, such an entity. It is likely that the protein generated from an ancestral sequence will have native folding and function (4, 5) , and the ancestral sequence is unlikely to change much as new sequences are added to the sample. We have developed a third, complementary means of developing a vaccine antigen that has all of the desirable properties of the ancestor but is less sensitive to phylogenetic outliers (e.g., Fig. 1 of Gaschen et al., seq. ZA). This new method identifies a point called point C, Center of the Tree (COT), on the unrooted phylogeny, where the average evolutionary distance from C to each tip on the phylogeny is minimized. Because the COT is a point on the phylogeny, the estimated COT sequence will have the same advantages as the estimated ancestral sequence. In the table, we show that, using the subtype C data presented in Gaschen et al., the COT is at least as similar to sampled amino acid sequences as the ancestor or the consensus, in the gag and env genes. Although the COT method is as good as either of the other methods at minimizing the differences in the context of subtype C, a real benefit from its use may accrue under different and equally important evolutionary scenarios. By design, the COT will be more similar than the ancestor to viral lineages or clades that have evolved more rapidly than other lineages, perhaps through strong diversifying selection, while maintaining similarity to more slowly evolving lineages. Thus, it may have a particular advantage when phylogenies are found to be more asymmetric, as in the case of trees involving multiple subtypes or recombinant forms.
An effective AIDS vaccine will need to provide broad protection against multiple HIV strains, particularly rapidly evolving ones. Minimizing the number of antigens, while maximizing the breadth of their reactivity, increases the feasibility of development and successful implementation of such a vaccine. To this extent, the COT may address the resulting trade-offs more equitably than either the consensus or the ancestor. Designing a vaccine capable of dealing with the extensive diversity of circulating HIV-1 strains worldwide is a daunting task, particularly in light of recent reports of intersubtype HIV superinfection (6). We believe the COT method provides an additional approach to vaccine design that could bridge the gap between highly specific monovalent and multivalent HIV vaccines. 
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THE COT METHOD, LIKE THE CONSENSUS AND
ancestral strategies (1), produces a central sequence suitable for testing as a vaccine candidate. All of these approaches reduce the average distance between a vaccine antigen and circulating HIV-1 proteins. For HIV-1 subtypespecific vaccine strategies, the three derived sequences will be only slightly different, each subject to different biases. The biological properties of vaccines derived from such artificial sequences cannot be predicted. Experiments directly comparing artificial and natural vaccines are needed to test their immunogenicity and extent of cross-reactive protection.
Within-clade HIV-1 sequences tend to give very short internal branch lengths near the basal node of the clade and long branch lengths from the tips to the interior nodes of the tree. In an idealized version of such "star" phylogenies, as illustrated in panel B of Nickle et al.'s figure, the ancestor and the COT coincide. In reality, there is some structure near the base of HIV-1 subtype trees (1, 2) , resulting in slight differences between the within-clade consensus, COT, and ancestral sequences. The COT and consensus sequences favor heavily sampled sublineages and deemphasize outliers. But in cases where the evolution of the virus is not timesymmetric-e.g., the accumulation of escape mutations in CTL epitopes presented by common HLA types in a given population- the consensus may produce a sequence bearing epitopes more relevant to the current epidemic than either the COT or ancestral state.
Nickle et al. write that "the ancestral state method… has an advantage over a consensus vaccine because the ancestral state is an estimate of an actual sequence that existed in the past." We reemphasize (1) that one should be cautious about supposing that reconstructed sequences are meaningfully similar to viral genomes that once existed. Ancestral and COT sequences are both artificial, defined as the most likely state, at a particular interior point in the tree, consistent with the observed data given the evolutionary model. Discordance between biological reality and the evolutionary model can lead to faulty inference of ancestral states. Evolutionary models generally capture the "average" evolutionary pattern over a region under consideration, rather than the nuances of individual sites and lineages, and models generally ignore recombination (3), correlation between sites, differences in mutational patterns induced by neighboring bases, and differing selective pressures in different regions and lineages. Such problems are apt to be most severe at sites with the greatest immunological significance, because these sites will be evolving under positive selection and are subject to between-site correlations, whereas the models assume neutral evolution and independence of sites. Also, the most likely ancestral state is, in fact, not very likely. For example, even ignoring errors in the evolutionary model and the tree, the probability that there are no errors in the C-subtype ancestor envelope sequence in our reconstruction (1) is 5 × 10 −15 , and the expected number of errors is 28 of 2379 sites (1.2%). The difference between the ancestor, consensus, and COT is of the same order as the expected number of errors (1.2%), indicating that there may be little statistical weight to the differences between the three sequences.
The bottom line for incorporating any sort of central, derived protein sequence into vaccines is experimentally determined preservation of key antigenic domains, cross reactivity, and immunogenicity. T cell epitopes are short processed peptides, and so the question of natural versus artificial proteins is of less concern in that context. Antibody epitopes, however, are often conformationally sensitive. We have recently found that a consensus M group gp120 protein bound to soluble CD4 as well as to neutralizing (b12 and 2G12) and conformation-sensitive (17b and A32) monoclonal antibodies (4) . Furthermore, this M consensus protein exhibited enhanced interclade antigenic cross reactivity (see figure) . These results indicate that it is premature to exclude any of the possible central immunogen approaches without rigorous and comparative testing.
